The Science of Running Economy / Special Feature on Female Runners Issue 7 (Physiology of Gender Differences) Are female runners 'slower' than men? If you line up the records, there is certainly an ...

If you use Leopard-EM in your research, please include these linked references: Citation (bottom of this page). @article {Giammar2025.08.26.672452, author = {Giammar, Matthew David and Dickerson, ...

Hockey is returning to the Houston area following an announcement by the North American Hockey League (NAHL) on Wednesday. According to a statement, the NAHL announced the Board of Governors has ...

The GSNN method is a algorithm that integrates prior knowledge of latent variable interactions directly into neural architecture. See the read-the-docs for documentation. @article ...

While electrokinetic transport underlies bioengineering and separation technologies, the roles of electrophoresis (EP) and electroosmosis in complex porous environments remain poorly understood. Here, ...

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the ...

Peter Thiel’s Armageddon speaking tour has—like the world—not ended yet. For a full two years now, the billionaire has been on the circuit, spreading his biblically inflected ideas about doomsday ...

UPDATE, Wednesday May 28: As of this morning, the two sides have returned to the bargaining table, union officials say. “Our workloads are unsustainable. It has been for many years. We’re all working ...

ESPN’s Los Angeles-based “SportsCenter” and soccer studio coverage out of the city are coming to an end, with plans to relocate the productions to Bristol, Connecticut. The sports network’s decision ...

What’s an A’s fan to do now? The franchise has, at least temporarily, set up shop in Sacramento after saying all of its goodbyes to Oakland and the Bay Area last summer. A permanent relocation to Las ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...